Immune cell study in hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had hidradenitis suppurativa for at least 6 months and it is moderate to severe.
- You are about to start a biologic medicine (adalimumab, secukinumab, or bimekizumab) within 7 days.
- You have at least one active sore in a spot that is not in a skin fold (like armpit or groin) and not on your face, where a small skin sample (biopsy) can be taken.
- You have not taken immunosuppressant drugs (including oral steroids or biologics) in the last 4 weeks, and you do not have diabetes, wound-healing problems, or allergies to local anesthetics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
This study uses MRI brain scans to see if brain activity differs in people with hidradenitis suppurativa (a painful skin condition) compared to healthy volunteers. It also tracks how treatment affects the brain over 3 months.
This study collects information from people with hidradenitis suppurativa (a skin condition causing painful lumps) to better understand the condition and improve care worldwide.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.